An NCI-designated Comprehensive Cancer Center
By City of Hope | October 8, 2018
Yuan Yuan, M.D., Ph.D., associate clinical professor, Department of Medical Oncology & Therapeutics Research, is the principal investigator in a new clinical trial that seeks to give new hope to breast cancer patients. This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.
The complementary modes of action and the low potential for overlapping toxicity make the combination of androgen receptor (AR) targeted therapy and immunotherapy one of the most promising treatment strategies for metastatic triple-negative breast cancer, which accounts for 15 to 20 percent of all breast cancers. These may also be more patient-friendly therapies as their mechanisms of action are not associated with the alopecia of traditional therapies.
An open-label phase 2 clinical trial is evaluating the combination of pembrolizumab and selective AR modulator GTx-024 in patients with advanced AR-positive triple-negative breast cancer. The primary endpoint is the safety and tolerability of the treatment regimen, as well as the response rate (CR or PR via RECIST 1.1). Clinical benefit rate, duration of response, progression-free survival and overall survival will also be used to measure efficacy.
For enrollment information, please contact Yuan by phone at 626-256-4673, ext. 89200, or by email at [email protected].

Subscribe to Physician News for the latest developments in diabetes and cancer prevention, treatment, research, clinical trials and upcoming continuing medical education (CME) programs.
We will always respect your privacy and you may unsubscribe at any time. We will never sell or exchange your information with others. View our complete Privacy Policy .

*Required Fields